** Divi's Laboratories DIVI.NS shares up 3.8%, top gainer in
Nifty pharma index .NIPHARM which is up 2.6%
** Citi says DIVI remains its top pick in Indian
pharmaceutical sector
** Brokerage expects DIVI's key drug Entresto active pharma
ingredient (API) sales to rise vs street expectations of decline
** DIVI likely to supply Entresto API to generics
manufacturers as well after patent expires - Citi
** DIVI snaps three-day losing streak
** Citi has "buy" rating on stock, with PT at 6,850 rupees
** Analysts on average rate stock a "hold", with median PT
at 5,285 rupees, per LSEG data
** DIVI up ~ 59% YTD vs ~32% gains in pharma index
(Reporting by Sethuraman NR)
((Sethuraman.NR@thomsonreuters.com; (+91 9945291420); Reuters
Messaging: nallur.sethuraman.thomsonreuters.com@reuters.net))